and 0.1% NaN 3 (buffer A), then used to screen furanocoumarin derivatives using ELISA.
Preparation of the Immunogen A solution of DHB (4.5 mg, 12 mmol) and succinic anhydride (12 mg, 120 mmol) in pyridine (300 ml) was stirred overnight at 60°C. After removing pyridine by passing nitrogen through the reaction mixture, 1 ml of ethyl acetate and 1 ml of H 2 O were added to the residue, and the mixture was shaken vigorously. The ethyl acetate layer was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and evaporated to give DHB hemisuccinate (3.4 mg) as a white solid. The resulting DHB hemisuccinate was used without further purification for preparing the conjugates with BSA and b-Gal, respectively, as the immunogen and the tracer in the ELISA. The yield of DHB hemisuccinate was tentatively estimated to be 60% according to HPLC measurements of the quantity of nonreacted DHB.
1-Ethyl-3,3-dimethylaminopropyl-carbodiimide hydrochloride (EDPC) (3 mg, 15.6 mmol) and N-hydroxysuccinimide (1.8 mg, 15.6 mmol) were added to a solution of DHB hemisuccinate (approximately 3.4 mg, 7.2 mmol) in 95% dioxane (0.5 ml), and the resulting solution was allowed to stand at room temperature for 2 h. After the addition of H 2 O, the resulting mixture was extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous sodium sulfate, and evaporated to give succinimidyl DHB hemisuccinate as a white solid. A solution of BSA (10 mg, 0.15 mmol) in 0.1 M phosphate buffer (pH 7.0, 1 ml) was mixed with a solution of succinimidyl DHB hemisuccinate (approximately 3.8 mg, 6.7 mmol) in N,N-dimethylformamide (DMF, 300 ml) and incubated at room temperature for 2 h. The reaction mixture was chromatographed on a Sephadex G-100 column (2.8ϫ 42 cm) with an eluant of 0.1 M phosphate buffer (pH 7.0) containing 3 M urea. Then the purified conjugate was examined spectrophotometrically and estimated to contain approximately 3.1 molecules of DHB per BSA molecule, assuming the molar extinction coefficients of DHB to be 5300 at 280 nm and 14300 at 310 nm, and those of BSA to be 43600 at 280 nm.
Antibody Production in Rabbits An aliquot, containing about 1 mg of the DHB-BSA conjugate, was emulsified with an equal volume of Freund's complete adjuvant. Two white female rabbits were each given multiple subcutaneous injections over sites along both sides of their backs. Booster injections were then given three times at biweekly intervals, using one-half the amount of the dose of the first immunization. The rabbits were bled from an ear vein 10 weeks after immunization began. The sera (10 ml) were separated by centrifugation and heated at 55°C for 30 min. Fractions of IgG were separated from the sera with 50% saturated ammonium sulfate and chromatographed on a column of DEAE-Sephacel (2.1ϫ23 cm) using 17.5 mM phosphate buffer (pH 6.8) as an eluant. 14) The fraction passed through the column was lyophilized and used as anti-DHB IgG for ELISA.
Enzyme Labeling DHB was labeled by binding to b-Gal, essentially by the same principle as used for the preparation of the DHB immunogen. In brief, a solution of b-Gal (156 mg, 0.28 nmol) in 1 ml of 0.1 M phosphate buffer (pH 7.0) was mixed with a solution of succinimidyl DHB hemisuccinate (approximately 0.2 mg, 0.35 mmol) in 50 ml of DMF and incubated at room temperature for 1 h. The mixture was chromatographed on a Sepharose 6B column (2.0ϫ40 cm) using 20 mM phosphate buffer (pH 7.0) containing 0.1 M NaCl, 1 mM MgCl 2 , 0.1% BSA, and 0.1% NaN 3 (buffer B) to remove any remaining small molecules. Four-milliliter fractions were collected, and fractions 15 to 17, representing the main peak showing enzyme activity, were combined and used as a label in the ELISA.
ELISA Method ELISA is based on the principle of competition between enzyme-labeled and unlabeled drugs for an immobilized antibody, followed by measurement of the marker enzyme activity of the immunocomplex bound to the solid phase. Briefly, the wells in microtiter plates (Nunc F Immunoplates I, Nunc, Reskilde, Denmark) were coated by loading 150 ml of anti-DHB IgG (0.5 mg/ml) in 10 mM Tris-HCl buffer (pH 8.5) containing 10 mM NaCl and 10 mM NaN 3 and allowed to stand for 1 h at 37°C. After the plates had been washed twice with buffer A, they were incubated with 200 ml of 10 mM Tris-HCl buffer (pH 8.5) containing 10 mM NaCl, 10 mM NaN 3 and 2% BSA for 20 min at 37°C to prevent nonspecific adsorption. The anti-DHB IgG-coated wells were then filled with 50 ml of either sample, or buffer A as a control, followed immediately by 50 ml of the pooled DHB-b-Gal conjugate (diluted 1 : 2000 in buffer A). The wells were then incubated for 3 h at room temperature and washed once again thoroughly with buffer A. The activity of the enzyme conjugate bound to each well was then measured by the addition of 125 ml of 0.1 mM 4methylumbelliferyl-b-D-galactopyranoside in buffer B, followed by incubation of the wells at 37°C for 30 min. The enzyme reaction was stopped by the addition of 75 ml of 0.5 M glycine-NaOH buffer (pH 10.3) to each well, and the fluorescence due to resulting 4-methylumbelliferone was measured at wavelengths of 355 nm for excitation and 460 nm for emission using a fluorescence microplate reader (Fluoroskan Ascent, Labsystems, Helsinki, Finland).
RESULTS AND DISCUSSION
As shown in Fig. 1 , six furanocoumarin derivatives isolated from GFJ contain a geranyloxy side chain(s). Bergamottin and DHB are the main furanocoumarin derivatives, all of which reduce CYP3A4 activities through both competitive and mechanism-based inhibition mechanisms. 6, 15, 16) Ohta et al. 17) reported that the presence of 5-geranyloxyfuranocoumarin moiety is essential for the CYP3A4 inhibition. Therefore, to develop an ELISA for screening of furanocoumarin derivatives as the CYP3A4 inhibitors, it is necessary to produce an anti-furanocoumarin derivative antibody that recognizes the 5-geranyloxyfuranocoumarin moiety of the furanocoumarin derivatives. DHB has two hydroxyl groups at the terminal of the geranyl group. Ohta et al. 17) reported that the hydroxy group at the C-6Ј position (Fig. 2) is readily available for introducing a reactive group into the molecule. Therefore, we chose this site to introduce the carboxylic group. DHB immunogen was prepared using the Nhydroxysuccinimide ester method as shown in Fig. 2 . The DHB-BSA conjugate, whose DHB/BSA molar ratio is about 3, induced the formation of specific antibodies in each of the two rabbits immunized.
The DHB-b-Gal conjugate was also prepared by essentially the same procedure. The conjugate thus obtained was stable in eluted buffer (pH 7.0) at 4°C for more than 6 months, during which no loss of enzyme activity or immunoreactivity was seen.
Using anti-DHB antibody and DHB-b-Gal as a tracer, an ELISA for DHB and bergamottin was developed (Fig. 3) . The sensitivities of DHB and bergamottin in the ELISA were shown to be 800 pg/ml with DHB and 4 ng/ml with bergamottin (amount of each compound at the B/B 0 values of 80%), respectively. Therefore, this ELISA may be sensitive enough to screen DHB and bergamottin.
The antibody specificity was determined by the cross-reactivity with other types of furanocoumarin derivatives, which were defined as the percentage of each compound to DHB in the concentrations required for 50% replacement of bound b-Gal activity. The anti-DHB antibody showed 17.2% cross-reaction with bergamottin and 0.28% with 5-methoxypsoralen; no detectable cross-reaction, however, was found with 8-methoxypsoralen (Table 2 ). These findings suggest that the antibody well recognizes both the furanocoumarin and 6,7-dihydroxy-3,7-dimethyloct-2-enyloxy moieties of DHB. Thus, the anti-DHB antibody recognizes 5-geranyloxyfuranocoumarin moiety that is essential for the CYP3A4 inhibition. The cross-reactivities of the other furanocoumarin derivatives isolated from GFJ have not yet been confirmed. However, it is estimated that they show similar cross-reaction to bergamottin or DHB judging from the specificity of the anti-DHB antibody. Therefore, this ELISA may be specific enough to screen furanocoumarin derivatives containing geranyloxy side chain as the inhibitor of CYP3A4 in GFJ.
Fifteen citrus fruit juices were examined for detection of furanocoumarin derivatives using the ELISA for DHB ( Table  3 ). Values of the immunoreactivity showed the amount (percentage) of bound enzyme activity for test samples (B) as a ratio of that bound using DHB-b-Gal alone (B 0 ). Therefore, 976 Vol. 27, No. 7 the higher B/B 0 value suggests a lower content, and the lower B/B 0 value means a higher content of DHB, bergamottin and/or the related furanocoumarin derivatives in the test sample. Eight (red pummelo, sweetie, melogold, banpeiyu pummelo, hassaku, sour orange, lime and natsudaidai) out of the 15 samples tested showed a significant immunoreactivity, indicating the existence of furanocoumarin derivatives. Five (red pummelo, 10) sweetie, 10) banpeiyu pummelo, 10) sour orange 18) and lime 19) ) of the 8 citrus fruits showing a significant immunoreactivity, have already been reported to contain furanocoumarin derivatives as the CYP3A4 inhibitors in GFJ. Therefore, it is estimated that melogold, hassaku and natsudaidai also contain the furanocoumarin derivatives. Navel orange, sweet orange and yuzu showed a slight immunoreaction. So far, there has been no report of the isolation of the furanocoumarin derivatives from these fruits, however, this result suggests the possibility that they do contain a small amount of the derivatives. On the other hand, no detectable immunoreaction was found in the other citrus fruits, and naturally they have not been reported to contain furanocoumarin derivatives. These results indicate that the ELISA for DHB may be a powerful tool for screening for these derivatives as CYP3A4 inhibitors. Guo et al. 10) reported that the inhibitory potency of GFJ samples tended to be higher with GFJ containing a higher amount of furanocoumarin derivatives. This raises the possibility that the citrus fruits showing a stronger immunoreactivity by the ELISA show a stronger drug interaction. This is the first report of screening for furanocoumarin derivatives in citrus fruits by ELISA. Besides the Rutaceae family, many plants of other families such as Umbelliferae, Leguminosae and Moraceae also contain furanocoumarin derivatives. 11) We are now trying to screen furanocoumarin derivatives using ELISA from a large number of crude drugs. 
